Is Insulet a Buy?
While cutting-edge technologies such as gene-editing and cancer immunology tend to get a lot of attention in the biotech world, one of the most lucrative niches in this area comes from treating a relatively common condition. Diabetes is quickly becoming one of the most prevalent diseases in the world. Right now, 425 million people around the world are living with the condition, and estimates suggest that number will grow to 629 million by 2045.
One promising diabetes stock is Insulet (NASDAQ: PODD), a well-known manufacturer of insulin pumps. While there are a couple of other noteworthy players in this market, Insulet has impressed investors and analysts alike with its consistent and impressive growth figures.
Is it enough to warrant a position in your portfolio, though? Let's look at some of the details and find out.
Source Fool.com
